The endocanabinnoid system and diabetes - critical analyses of studies conducted with rimonabant.
TLDR
The effects of rimonabant treatment in obese patients with cardiovascular risk factors to usual obesity pharmacological treatment is compared.Abstract:
Rimonabant is the first CB1 receptor inhibitor available in the Brazilian market. This new drug has been approved for the treatment of obese or overweight patients associated with cardiovascular risk factors. In this article it is compared the effects of rimonabant treatment in obese patients with cardiovascular risk factors to usual obesity pharmacological treatment.read more
Citations
More filters
Journal ArticleDOI
The multiple functions of the endocannabinoid system: a focus on the regulation of food intake
TL;DR: The endocannabinoid system has important physiological functions not only in the central nervous system but also in peripheral tissues, and the pharmacological modulation of the over-activity of this system could be useful in the treatment of the metabolic syndrome.
References
More filters
Journal ArticleDOI
Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia
TL;DR: Selective CB1-receptor blockade with rimonabant significantly reduces body weight and waist circumference and improves the profile of several metabolic risk factors in high-risk patients who are overweight or obese and have an atherogenic dyslipidemia.
Journal ArticleDOI
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Robin Christensen,Pernelle Kruse Kristensen,Pernelle Kruse Kristensen,Else Marie Bartels,Henning Bliddal,Arne Astrup +5 more
TL;DR: The findings suggest that 20 mg per day rimonabant increases the risk of psychiatric adverse events--ie, depressed mood disorders and anxiety-despite depressed mood being an exclusion criterion in these trials.
Journal ArticleDOI
Effect of sibutramine on weight maintenance after weight loss: a randomised trial
W. Philip T. James,Arne Astrup,Nick Finer,Jannik Hilsted,Peter Kopelman,Stephan Rössner,Wim H. M. Saris,Luc Van Gaal +7 more
TL;DR: Changes in concentrations of HDL cholesterol, VLDL cholesterol, and triglyceride, but not LDL cholesterol, exceed those expected either from weight loss alone or when induced by other selective therapies for low concentrations of LDL cholesterol relating to coronary heart disease.
Journal ArticleDOI
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
TL;DR: 20 mg/day rimonabant, in combination with diet and exercise, can produce a clinically meaningful reduction in bodyweight and improve HbA1c and a number of cardiovascular and metabolic risk factors in overweight or obese patients with type 2 diabetes inadequately controlled by metformin or sulphonylureas.
Journal ArticleDOI
Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action.
TL;DR: Research carried out in the past six years has confirmed a similarity between the endocannabinoids and the psychoactive substance in marijuana, delta9(-)-tetrahydrocannabinol, and suggested a role for endoc cannabinoidoids in the modulation of neurotransmitter action and release.
Related Papers (5)
Sibutramine: current status as an anti-obesity drug and its future perspectives.
Bikash Sharma,David C. Henderson +1 more